Waystar (WAY) processes 60% of US patient claims volume — 7.5B transactions and $2.4T in gross claims annually — through a payments + revenue cycle management platform. The Q1 2026 10-Q (filed 2026-04-29) shows revenue +22.4%, R&D +65.8%, EBITDA margin +110bps. The stock printed a fresh 52-week low the same day at 10.8x forward P/E. yfinance reports 95% idio variance — the drawdown is virtually entirely company-specific, not factor or sector.

What the Filing Shows

Revenue $313.9M, +22.4% YoY. Subscription +37.7%, mix shifting from 48.8% → 54.9% of total. Gross margin (ex-D&A) 69.1%, +160bps. Adj EBITDA $135.4M at 43.1% margin (+110bps).

The headline operating-line move: R&D expense +65.8% YoY to $18.4M, with capitalized software development +76% (total development investment $26.3M, +68%). This is the Iodine Software integration ($1.26B acquired Oct 2025) plus continued AltitudeAI development.

Peer cross-check makes the R&D number actionable rather than narrative. Healthcare HIT cohort Q1 2026: HCAT R&D -14% YoY (second consecutive year, plus Project Nexus 9% workforce reduction announced April 24). SOLV (3M HIM legacy clinical documentation incumbent) R&D -2.1%, operating income -47%. TDOC tech & dev -3.0%. WAY is the only HIT peer combining accelerating absolute R&D, accelerating capitalized software, and accelerating revenue concurrently. Three direct clinical-documentation-AI competitors are actively retreating as WAY scales investment.

NRR 110.5% (trailing 12-month) vs 113.5% prior year. The filing acknowledges both periods include the Feb 2024 Change Healthcare cyberattack tailwind. DOCS reports -500bps and HCAT -900bps in the same window — the compression is sectoral cyberattack-tailwind unlap, not WAY-specific churn. WAY's >$100K client count grew 15.2% YoY, confirming enterprise traction.

Option forfeitures 836K vs 31K prior year (27x increase) — most likely Iodine integration headcount rationalization. Single-quarter spike post-acquisition is normal; sustained spike in Q2 would not be.

What the Market Prices

Stock $19.90, 1% of 52-week range, RSI 22.8, -51.5% over 1Y. Forward P/E 10.8x vs HIT software peer median 18-22x. 23 Buy / 1 Hold sell-side consensus, mean target $34.74 (+74.6%) reiterated post-print by JPM, UBS, BofA, Needham, Citi.

The options tape diverges from the chart: P/C 0.02, calls IV 8.2% above puts (uncommon — market typically prices crash insurance), $32 OTM calls traded 5.6x open interest. Insider Heidi Miller (Director) bought $189K open-market on March 2 at ≈$26 (Form 4 code P) — the only conviction signal in the insider table; underwater.

Why the Gap Exists

Three reasons. (1) The R&D divergence requires synthesizing across 7+ peer filings; HCAT's Project Nexus RIF announcement preceded WAY's print by 5 days, and no single sell-side note connects them. (2) NRR compression looks idiosyncratic when read WAY-only, but cohort comparison shows WAY at the shallowest compression — sell-side rarely cross-references retention metrics across HIT peers. (3) -51% on accelerating numbers implies an unidentified seller. Bain Capital and EQT pre-IPO sponsor reduction is one hypothesis; lock-up tail unwind another. We have not identified the seller, and that uncertainty is real, not rhetorical.

Forward Math

At 8x EBITDA — a deeply distressed PE take-private multiple — equity value works out to roughly $21/share. Spot trades below it. At a 14x peer-discount forward P/E (vs median 18-22x), $25.80. At sell-side mean target multiple, $34.74. The filing-derived forward EPS is approximately the same at all three numbers; the spread is multiple, not earnings.

Sharpe at 95% idio variance, σ_idio 41%, expected return +25 to +35% over 12-18 months: forward Sharpe roughly 0.6, with right-tail M&A optionality not symmetrically captured.

Risks (ranked)

1. Epic UGM 2026 (Aug-Sep, Verona WI): highest-impact single risk. If Epic announces native clinical documentation AI bundled in EHR (DAX-Microsoft precedent), Iodine's value prop for Epic-shop hospitals collapses.
2. Iodine integration falters: Q2 2026 forfeitures sustain at elevated levels and NRR breaks 105% normalized.
3. Informed seller: the chart may contain real bearish information that the filing alone does not capture.
4. NRR breaks cohort path: WAY drops below 105% normalized while DOCS and HCAT stabilize.

Catalysts

• ~mid-May 2026 — HCAT Q1 2026 10-Q files. Confirms or breaks the lane-clearing premise.
• 2026-07-29 — WAY Q2 2026 earnings preview.
• 2026-08-08 — WAY Q2 2026 10-Q. R&D growth, option forfeitures, and NRR all resolve simultaneously.
• Aug-Sep 2026 — Epic UGM 2026 (Verona, WI).

What Would Change Our Mind

• HCAT Q1 print shows R&D rising despite the Project Nexus narrative — lane-clearing thesis breaks.
• WAY Q2 NRR drops below 105% normalized — bear leg becomes idiosyncratic, not sectoral.
• Epic UGM announces native clinical documentation AI module — competitive lane closes.
• WAY Q2 R&D moderates below 30% growth — was Iodine integration spike, not durable AI capex.
• Identified mechanical seller (Bain or EQT secondary disclosed, lock-up unwind quantified) — the chart's negative information becomes benign.

Evidence